COMPLETEDPHASE1

Sipuleucel-T and Ipilimumab for Advanced Prostate Cancer

Phase 1 Study of Sipuleucel-T and Ipilimumab in Combination for Advanced Prostate Cancer

NCT01832870•Prostate Oncology Specialists, Inc.

Summary

This is a clinical trial designed to quantify the immune response and determine the tolerability and side effects of sipuleucel-T when given in combination with ipilimumab for patients with advanced prostate cancer.

Eligibility

Age

18 - No limit years

Sex

MALE

Healthy Volunteers

No

Inclusion Criteria

•Subjects with advanced prostate cancer who are eligible to receive sipuleucel-T in accordance with FDA approved labeling of sipuleucel-T
•Subjects must understand and sign an informed consent form

Locations (1)

Prostate Oncology Specialists, Inc.

Marina del Rey, California, United States

Key Dates

Start Date

April 1, 2013

Primary Completion Date

February 1, 2016

Completion Date

February 1, 2016

Last Updated

August 24, 2017

Enrollment

9

ACTUAL participants

Conditions

Prostate CancerCastrate Resistant Prostate Cancer

Interventions

sipuleucel-T

DRUG

ipilimumab

DRUG

Testing the Safety and Effectiveness of Radiation-based Treatment (Lutetium Lu 177 Dotatate) for Metastatic Prostate Cancer That Has Neuroendocrine Cells

NCT05691465

Metastatic Prostate Adenocarcinoma With Neuroendocrine DifferentiationMetastatic Prostate Neuroendocrine Carcinoma+2 more

View study

RECRUITINGPHASE2

A Study of FG-3246 in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC)

NCT06842498

Metastatic Castration-Resistant Prostate Cancer

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: August 24, 2017Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

RECRUITINGPHASE2